Technical Analysis for RHHBY - Roche Hldg Ltd Spons

Grade Last Price % Change Price Change
grade A 31.05 -0.13% -0.0400
RHHBY closed down 0.13 percent on Monday, December 17, 2018, on 56 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical RHHBY trend table...

Date Alert Name Type % Chg
Dec 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Dec 17 Down 3 Days in a Row Weakness 0.00%
Dec 14 Fell Below 20 DMA Bearish -0.13%
Dec 14 Cup with Handle Other -0.13%
Dec 14 Volume Surge Other -0.13%
Dec 14 NR7 Range Contraction -0.13%
Dec 14 Gapped Down Weakness -0.13%
Dec 13 Cup with Handle Other -2.66%
Dec 12 Pocket Pivot Bullish Swing Setup -3.75%
Dec 12 Volume Surge Other -3.75%

Older signals for RHHBY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Is RHHBY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Dec 17 Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU
Dec 17 Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod
Dec 17 J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc
Dec 17 PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA)
Dec 14 FDA approves Celltrion's biosimilar to Roche's Herceptin
Dec 14 Pfizer's cut-price version of Avastin wins EU panel greenlight
Dec 14 5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
Dec 14 Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
Dec 12 Roche to Create Companion Diagnostic Test for Merck's Keytruda
Dec 11 Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO
See more RHHBY news...
Indicators
Indicator Value
52 Week High 33.82
52 Week Low 26.3
Average Volume 1,352,708
200-Day Moving Average 29.4234
50-Day Moving Average 30.8309
20-Day Moving Average 31.5773
10-Day Moving Average 31.709
Average True Range 0.5266
ADX 12.88
+DI 24.36
-DI 32.7581
Chandelier Exit (Long, 3 ATRs ) 31.0002
Chandelier Exit (Short, 3 ATRs ) 32.0698
Upper Bollinger Band 32.5278
Lower Bollinger Band 30.6268
Percent B (%b) 0.22
BandWidth 6.020147
MACD Line 0.182
MACD Signal Line 0.2955
MACD Histogram -0.1135
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.7250
Resistance 3 (R3) 31.7367 31.5233 31.6125
Resistance 2 (R2) 31.5233 31.3514 31.5175 31.5750
Resistance 1 (R1) 31.2867 31.2452 31.1800 31.2750 31.5375
Pivot Point 31.0733 31.0733 31.0200 31.0675 31.0733
Support 1 (S1) 30.8367 30.9014 30.7300 30.8250 30.5625
Support 2 (S2) 30.6233 30.7952 30.6175 30.5250
Support 3 (S3) 30.3867 30.6233 30.4875
Support 4 (S4) 30.3750